Form
SCHEDULE 13D/A
Active or control-oriented beneficial ownership filing.
Wei-Wu He - 09 Feb 2026 SCHEDULE 13D/A Report for CASI Pharmaceuticals, Inc. Ordinary Shares (CASI)
- Filing manager
- Wei-Wu He
- Reporting owner
- WEI-WU HE, Ph.D.
- Beneficially owned shares
- 13,965,535 shares
- Large-stake signal
-
Ownership
45%Beneficial ownership of this reported class.
Shares
13,965,535 sharesShares beneficially owned as disclosed.
Event date
09 Feb 2026Date tied to the ownership event or amendment.
Accepted by SEC
10 Feb 2026EDGAR acceptance date.
How to read this large-stake filing
- Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
- Compare this filing with the holder history and issuer page before treating the percentage as a current position.
- Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
- Class ownership
- 45%
- Symbol
- CASI
- Shares outstanding
- 30,761,090 shares
- SEC form
- SCHEDULE 13D/A
- Accepted by SEC
- 10 Feb 2026, 06:01:54 UTC
- Event date
- 09 Feb 2026
- Prior SEC filing
- 29 Jan 2026
- Next SEC filing
- 23 Mar 2026
- Source filing
- View source filing
Ownership signal
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Subject security
Names, identifiers, and filing context for this profile.
2 source fields
Source evidence
Original filing metadata and source links for verification.
6 source fields
Key filing fact
Wei-Wu He disclosed 45% ownership in CASI Pharmaceuticals, Inc. Ordinary Shares (CASI) on 09 Feb 2026.
Key facts
- Wei-Wu He filed SCHEDULE 13D/A for CASI Pharmaceuticals, Inc. Ordinary Shares (CASI).
- Disclosed ownership: 45%.
- Date of event: 09 Feb 2026.
Change
- Previous schedule filing date: 29 Jan 2026.
- Current filing was accepted on 10 Feb 2026, 06:01.
Research use
- This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
- Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.
Evidence
Backed by Schedule 13D/13G
View source filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Disclosed reporting parties (7)
Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares owned | Sole voting power | Shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| WEI-WU HE, Ph.D. | 45% | 13,965,535 | 2,130,550 | 11,834,985 | /s/ Wei-Wu He, Ph.D. | Wei-Wu He, Ph.D. | 0001542073 |
| HUIYING MEMORIAL FOUNDATION | 3.1% | 637,644 | 0 | 637,644 | /s/ Wei-Wu He, Ph.D. | Wei-Wu He, Ph.D./President | |
| EMERGING TECHNOLOGY PARTNERS, LLC | 5.3% | 1,097,341 | 0 | 1,097,341 | /s/ Wei-Wu He, Ph.D. | Wei-Wu He, Ph.D./ Managing Member | |
| ETP Global Fund L.P. | 3.7% | 753,234 | 0 | 753,234 | EMERGING TECHNOLOGY PARTNERS, LLC | General Partner | |
| ETP BIOHEALTH III FUND, L.P. | 1.5% | 300,000 | 0 | 300,000 | EMERGING TECHNOLOGY PARTNERS, LLC | General Partner | |
| HE Family GRAT | 0.5% | 100,000 | 0 | 100,000 | /s/ Wei-Wu He, Ph.D. | Wei-Wu He, Ph.D./Trustee | |
| ETP Global Fund III L.P. | 33% | 10,000,000 | 0 | 10,000,000 | EMERGING TECHNOLOGY PARTNERS, LLC | General Partner |
CIK / CUSIP context first